Pulmatrix IncNASDAQ:PULM
- LAST PRICE2.0500
- TODAY'S CHANGE (%)-0.0190 (-0.9183%)
- Bid / Lots2.0000/ 12
- Ask / Lots2.0700/ 8
- Open / Previous Close2.0900 / 2.0690
- Day Range
- 52 Week Range
- Volume6,385
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PULM |
|---|---|---|
| 09:32 ET | 423 | 2.09 |
| 12:10 ET | 100 | 2.1024 |
| 12:51 ET | 368 | 2.1 |
| 01:36 ET | 321 | 2.1 |
| 03:35 ET | 100 | 2.05 |
| 03:51 ET | 175 | 2.05 |
Nov 8, 2024
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update, from 10:26AM ET on Friday Nov 08, 2024 by Dow Jones
10:26AM ET on Friday Nov 08, 2024 by Dow Jones*DJ Pulmatrix 3Q Loss/Shr 71c >PULM, from 10:26AM ET on Friday Nov 08, 2024 by Dow Jones
10:26AM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pulmatrix Inc | 7.5M | -0.7x | --- |
Correlate Energy Corp | 4.0M | -0.1x | --- |
Redhill Biopharma Ltd | 9.2M | 0.0x | --- |
Fresh Tracks Therapeutics Inc | 4.4M | -0.5x | --- |
International Stem Cell Corp | 481.1K | -0.9x | --- |
Kineta Inc | 7.6M | -0.3x | --- |
Company Information
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Contact Information
- Headquarters
- 945 CONCORD STREET, SUITE 1217FRAMINGHAM, MA, United States 01701
- Phone
- 781-357-2333
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Michael Higgins
- Interim Chief Executive Officer, Interim Chief Financial Office
- Peter Ludlum
- Vice President - Finance
- Michelle Siegert
- Independent Director
- Richard Batycky
- Independent Director
- Todd Bazemore
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.6M |
|---|---|
Revenue (TTM) | $11.4M |
Shares Outstanding | 3.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-2.97 |
Book Value | $4.93 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -99.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
